skip to navigation skip to content

Nature: Corporate venture capital and Cambridge


The challenge today is that traditional venture capital has largely moved away from early stage innovations, seeking the safety of more developed, de-risked technologies for their portfolio pipeline. By contrast, the pharmaceutical industry has demonstrated a growing interest in this field and is now a major player in funding biotech startups.

Research co-authored by Dr Shima Barakat, Research and Teaching Fellow at the Centre for Entrepreneurial Learning (CfEL), and Dr Shailendra Vyakarnam, Director of the Centre for Entrepreneurial Learning CfEL), is published in Nature.

Read the full article []